LaiKai Medicine (02105.HK): The first subject of the Phase I multiple dose expansion study of LAE102 for the treatment of obesity has been dosed.

The Zhitong Finance and Economics APP news, Lai Kai Medicine-B (02105.HK) announced that the group has initiated the enrollment of subjects for the Phase I multiple-dose expansion study of LAE102 for the treatment of obesity in China, and the first subject has already been dosed.